Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Key Points

• Immunic reported quarterly EPS of ($0.80), beating analysts’ consensus estimate of ($1.16) by $0.36.
• IMUX opened at $14.62, with a market capitalization of approximately $199 million; the stock has traded between $5.06 and $15.84 over the past year.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $47.57 target price, while institutional investors and hedge funds own 51.82% of the shares.

Immunic (NASDAQ:IMUX - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.36, FiscalAI reports.

Immunic Stock Performance

NASDAQ:IMUX opened at $14.62 on Tuesday. The stock has a market cap of $199.12 million, a price-to-earnings ratio of -2.60 and a beta of 1.41. Immunic has a one year low of $5.06 and a one year high of $15.84. The business's 50-day simple moving average is $14.29 and its 200 day simple moving average is $11.84.

Wall Street Analysts Forecast Growth

IMUX has been the topic of a number of recent research reports. B. Riley Financial reduced their target price on shares of Immunic from $40.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 22nd. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. LADENBURG THALM/SH SH upgraded Immunic to a "strong-buy" rating in a research note on Wednesday, July 29th. D. Boral Capital lowered Immunic from a "buy" rating to a "hold" rating in a research note on Wednesday, April 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunic in a research note on Friday, May 29th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $47.57.

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC increased its stake in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares during the last quarter. Vanguard Group Inc. grew its position in Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company's stock valued at $3,832,000 after buying an additional 219,957 shares in the last quarter. Squarepoint Ops LLC bought a new position in Immunic in the 3rd quarter valued at about $239,000. Two Sigma Investments LP acquired a new position in Immunic during the 3rd quarter valued at about $52,000. Finally, Virtu Financial LLC acquired a new stake in shares of Immunic in the 3rd quarter worth approximately $99,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source